Monday, November 2, 2026
Barclays kept its Overweight rating on Kymera Therapeutics (KYMR) and raised its price target to $170 from $139.
Friday, October 30, 2026
Truist Securities kept its Buy rating on Kymera Therapeutics (KYMR) and raised its price target to $150 from $136.
RBC Capital kept its Sector Perform rating on Kymera Therapeutics (KYMR) and raised its price target to $116 from $115.
Tuesday, October 27, 2026
Morgan Stanley kept its Overweight rating on Kymera Therapeutics (KYMR) with a price target of $146.
Friday, October 9, 2026
Raymond James started coverage of Kymera Therapeutics (KYMR) with an Outperform rating and a price target of $140.
Monday, October 5, 2026
Citi kept its Buy rating on Kymera Therapeutics (KYMR) with a price target of $150.
Tuesday, September 22, 2026
Stifel kept its Buy rating on Kymera Therapeutics (KYMR) with a price target of $152.
Monday, September 14, 2026
BofA Securities kept its Buy rating on Kymera Therapeutics (KYMR) and raised its price target to $144 from $125.
Thursday, September 10, 2026
Wolfe Research upgraded Kymera Therapeutics (KYMR) to Outperform.
Monday, August 31, 2026
Guggenheim kept its Buy rating on Kymera Therapeutics (KYMR) and raised its price target to $170 from $135.
Thursday, August 27, 2026
Wells Fargo kept its Overweight rating on Kymera Therapeutics (KYMR) with a price target of $151.
Frequently asked questions
What is the latest news on KYMR?
Nov 2, 2026: Barclays kept its Overweight rating on Kymera Therapeutics (KYMR) and raised its price target to $170 from $139. (Barclays) · Oct 30, 2026: Truist Securities kept its Buy rating on Kymera Therapeutics (KYMR) and raised its price target to $150 from $136. (Truist Securities) · Oct 30, 2026: RBC Capital kept its Sector Perform rating on Kymera Therapeutics (KYMR) and raised its price target to $116 from $115. (RBC Capital)
What are analysts saying about KYMR?
Nov 2, 2026: Barclays kept its Overweight rating on Kymera Therapeutics (KYMR) and raised its price target to $170 from $139. · Oct 30, 2026: Truist Securities kept its Buy rating on Kymera Therapeutics (KYMR) and raised its price target to $150 from $136. · Oct 30, 2026: RBC Capital kept its Sector Perform rating on Kymera Therapeutics (KYMR) and raised its price target to $116 from $115.
Get KYMR news as it happens
Every headline, SEC filing and analyst action for KYMR on your live chart, with important news marked and alerts when it matters.
Try SEPT Free